2023
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I
Unger J, Qian L, Redman M, Tavernier S, Minasian L, Sigal E, Papadimitrakopoulou V, Leblanc M, Cleeland C, Dzingle S, Summers T, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray J, Kelly K, Gandara D, Bazhenova L, Herbst R, Gettinger S, Moinpour C. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. Journal Of The National Cancer Institute 2023, 115: 437-446. PMID: 36625510, PMCID: PMC10086628, DOI: 10.1093/jnci/djad003.Peer-Reviewed Original ResearchConceptsQuality of lifeComposite risk modelAppetite lossSeverity scoreWeek 13Advanced squamous cell lung cancerWeek 7Baseline patient-reported outcomesRandomized phase III trialSquamous cell lung cancerPhase III trialsRisk of progressionShortness of breathCell lung cancerPatient-reported outcomesRisk of deathMultivariable linear regressionEffect of treatmentEvaluable patientsPrimary endpointIII trialsOverall survivalMedian ageAdvanced cancerPrognostic relevance
2015
Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
Paz-Ares L, Horn L, Borghaei H, Spigel D, Steins M, Ready N, Chow L, Vokes E, Felip E, Holgado E, Barlesi F, Kohlhaeufl M, Rodriguez O, Burgio M, Fayette J, Gettinger S, Harbison C, Dorange C, Finckenstein F, Brahmer J. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2015, 33: lba109-lba109. DOI: 10.1200/jco.2015.33.18_suppl.lba109.Peer-Reviewed Original ResearchNon-squamous cell non-small cell lung cancerPlatinum-based doublet chemotherapyProgression-free survivalSuperior overall survivalPD-L1 expressionOverall survivalDeath-1 immune checkpoint inhibitor antibodyInvestigator-assessed objective response rateGlobal phase III studyImmune checkpoint inhibitor antibodyNon-small cell lung cancerRandomized phase III trialCheckpoint inhibitor antibodyDrug-related AEsObjective response rateSubsequent systemic therapyTrials of nivolumabPhase III studyPhase III trialsCell lung cancerTyrosine kinase inhibitorsQuality of lifeDoublet chemotherapyIII studyIII trials
2012
1231PD Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)
Blackhall F, Evans T, Han J, Salgia R, Moro-Sibilot D, Gettinger S, Crino L, Wilner K, Reisman A, Iyer S. 1231PD Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC). Annals Of Oncology 2012, 23: ix402. DOI: 10.1016/s0923-7534(20)33882-5.Peer-Reviewed Original ResearchAdvanced ALK-positive NSCLCGlobal QOLPatient-reported symptomsALK-positive NSCLCQuality of lifePatient-reported outcomesMeaningful improvementsSmall cell lung cancerEffect of crizotinibEfficacy of crizotinibLung cancer moduleMajority of patientsALK-Positive NonLung cancer symptomsCell lung cancerEnd of treatmentHigh response rateHigher symptom severityCrizotinib treatmentCancer QuestionnaireSecondary endpointsMedian ageConclusions TreatmentCancer ModuleQLQ-C30
2010
Management of Patients with Advanced Non-Small Cell Lung Cancer
Triano LR, Deshpande H, Gettinger SN. Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 2010, 70: 167-179. PMID: 20108990, DOI: 10.2165/11532200-000000000-00000.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerEpidermal growth factor receptorGrowth factor receptorOverall survivalLung cancerThird-line treatmentFirst-line chemotherapyFactor receptorManagement of patientsVascular endothelial growth factorQuality of lifeEndothelial growth factorMedian survivalSystemic therapyRandomized trialsTraditional chemotherapySmall molecule inhibitorsFDA approvalUS FDAChemotherapyKey mediatorGrowth factorAdditional agents